

**The Role of Intraperitoneal Chemotherapy in Treatment of Primary &  
Recurrent Epithelial Ovarian Carcinoma**

**THESIS**

**Submitted for partial fulfillment of**

**Master degree in clinical oncology**

**PRESENTED BY**

**Rasha Salama Mohammed**

M.B.B.Ch, Cairo University

**SUPERVISORS**

**PROF.Dr.Kamal EL-Ghamrawy (M.D, FRCR)**

Professor of clinical oncology

Faculty of medicine

Cairo University

**Prof.Dr.Farouk Ahmmed Hagag (M.D)**

Professor of clinical oncology

Faculty of medicine

Cairo University

**Dr.Osama Taha (M.D)**

Lecturer of clinical oncology

Faculty of medicine

Cairo University

**Faculty of medicine**

**Cairo University**

**2009**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

2  
مَدِينَةُ

جامعة القاهرة / كلية الصيد  
الدراسات العليا

محضر  
اجتماع لجنة الحكم على الرسالة المقدمة من  
الطبيبة / د. سحر كرم  
توظنة للحصول على درجة الماجستير / الدكتوراه  
فى علاج الأورام

تحت عنوان : باللغة الانجليزية :  
The role of intraperitoneal chemotherapy in treatment of Primary & Rec. Ovarian Carcinoma  
باللغة العربية : د. د. رحمن العليج الطبيب فى علاج أورام  
عشاء المسكن الادوية والقانونية

- بناء على موافقة الجامعة بتاريخ ١١ / ٩ / ٢٠٠٩ تم تشكيل لجنة للفحص والمناقشة  
للمرسلة المذكورة أعلاه على النحو التالي :-  
١. د. د. كمال عبد الغفار عن المشرفين  
٢. د. د. جمال صايد ممتحن داخلي  
٣. د. د. خالد يوسف ممتحن خارجي

بعد فحص الرسالة بواسطة كل عضو منفردا وكتابة تقارير منفردة لكل منهم لتعقدت للجنة  
مجتمعة فى يوم الاربعاء بتاريخ ١٤ / ٩ / ٢٠٠٩ بقسم علاج الأورام مدرج ٧ الطبيب  
بكلية الطب - جامعة القاهرة وذلك لمناقشة الملأب فى جلسة علنية فى موضوع الرسالة وللنتائج  
التي توصل اليها وكذلك الأسس العلمية التي قام عليها البحث .  
قرار اللجنة :

قبول الرسالة وتذرع على المجلس

الممتحن الخارجى  
د. د. كمال

الممتحن الداخلى  
د. د. جمال

توقيعات أعضاء اللجنة :-  
للمشرف الممتحن

عصام

# **Abstract**

A combination of IV and IP administration of chemotherapy conveys a significant survival benefit among women with optimally debulked epithelial ovarian cancer, compared to IV administration alone. The three largest studies with the greatest survival advantage delivered cisplatin 100 mg/m<sup>2</sup> IP. , the chemotherapy regimens mandated modification based on patient tolerance.

The benefit appears to be approximately a 12-month improvement in median overall survival. It may also be associated with a significantly increased short-term risk of toxicity compared with IV chemotherapy; however, the toxicity is short-term and manageable.

## **Key words:**

The combination of IV and IP- survival benefit- debulked epithelial ovarian cancer-12-month improvement in median overall survival-toxicity

## ACKNOWLEDGEMENTS

First and foremost, my deep praises are due to Almighty "Allah" who enabled me to finish this piece of work appropriately and rapidly.

I express my utmost gratitude to the eminent **Prof .Dr. Kamal El -Ghamrawy** professor of oncology Cairo university , for giving me the privilege of working under his meticulous and kind supervision ; for his constant support ; valuable encouragement and guidance for every word in this work.

I also owe my sincere and gratitude to **Prof.Farok Hagag** Professor of oncology Cairo university, for his great support, his experience he gave me, patience and fruitful comments without this work would have never been accomplished.

Moreove, I would like to thank heartily Dr. Osama Taha lecturer of oncology Cairo university for his kind supervision and great help through this work.

Rasha Salama Mohammed

## Contents

	<b>Page</b>
List of Tables	
List of Figures	
Introduction & Aim of work	١
<b><u>Review of literature</u></b>	
<b>Chapter(1):</b> clinical profile and general outlook on the tratment of ovarian cancer	<b>٥</b>
<b>Chapter(2):</b> Anatomical considerations Intraperitoneal chemotherapy	<b>34</b>
Recommendation& Dicscussion	<b>100</b>
Summary & conclusions	<b>103</b>
References	<b>105</b>
Arabic summary	

## Table of Contents

<b>INTRODUCTION &amp; AIM OF WORK .....</b>	<b>1-4</b>
---	------------

<b>CHAPTER (ONE) CLINICAL PROFILE AND GENERAL OUTLOOK ON THE TRATMENT OF OVARIAN CANCER .....</b>	<b>5-33</b>
---	-------------

- ..... E  
PIDEMIOLOGY
- ..... N  
ATURAL HISTORY AND PATTERN OF SPREAD
- ..... D  
IAGNOSIS AND SCEERING
- ..... T  
REATMENT OF EARLY STAGE EPITH. OVARIAN CANCER
- ..... T  
ERATMENT OF ADVANCED EPITH. OVARIAN CANCER
- TREATMENT OF RECURRENT OVARIAN CANCER
- TARGETED THERAPY FOR OVARIAN CANCER

<b>CHAPTER( TWO): INTRAPERITONEAL CHEMOTHERAPY ...</b>	<b>34-99</b>
--	--------------

- ..... A  
NATOMICAL CONSIDERATION
- DEFINITION OF IP CHEMOTHERAPY
- RATIONAL OF IP CHRMOTHERAPY
- PRINCIPLES OF SELECTION OF DRUGES USED FOR IP CHEMOTHERAPY
- PHAMACOKINETICS OF IP CHEMOTHERAPY
  - a) THORETICAL CONSIDERATION
  - b) CLINICAL STUDIES
- CLINICAL TRIALS OF IP CHEMOTHERAPY
- TECHNIQUE OF IP CHEMOTHERAPY
- TOXICITY OF IP CHEMOTHERAPY
- COST EFFECTIVENESS

<b>Recommendations &amp; Discussions .....</b>	<b>100-102</b>
--	----------------

<b>SUMMARY AND CONCLUSION .....</b>	<b>103-104</b>
-------------------------------------	----------------

<b>References .....</b>	<b>105-126</b>
-------------------------	----------------

## List of tables

<b>Tables</b>		<b>Page</b>
١.١	Effect of optimal primary cytoreduction on survival in advanced ovarian cancer	<b>30</b>
٢.١	Randomized trial comparing IP versus IP/IV first lin treatment of ovarian cancer	<b>52</b>
٢.٢	Randomized trial comparing surveillance to IP consolidation treatment	<b>53</b>
٢.٣	Median survival time for randomized comparing IV versus IV/IP first line treatment of ovarian cancer	<b>53</b>
٢.٤	Median survival time for randomized comparing surveillance to IP consolidation treatment	<b>53</b>
٢.٥	Randomized GOG phase 3 studies with IP chemotherapy	<b>٦٦</b>
٢.٦	Reasons why experimental IP arm in GOG 172 cannot be regarded as standard	<b>٦٦</b>
٢.٧	Characteristic of the patients in GOG trial	<b>71</b>
٢.٨	List of adverse events	<b>75</b>
٢.٩	Reported toxicity	<b>95</b>
٢.١٠	FIGO staging for ovarian cancer	<b>98-99</b>



## List of figures

<b>Figure</b>		<b>Page</b>
<b>۱.۱</b>	Extent of recurrent disease after cytoreductive surgery	<b>30</b>
<b>۲.۱</b>	Anatomy of the peritoneum	<b>34</b>
<b>۲.۲</b>	Schematic diagram of the principle of intraperitoneal chemotherapy	<b>43</b>
<b>۲.۳</b>	Schematic diagram of the decrease in drug concentration as a function of distance of penetration into the tumour nodule	<b>46</b>
<b>۲.۴</b>	The Hazard Ratio for PFS in IP VS IV therapy	<b>54</b>
<b>۲.۵</b>	The Hazard Ratio for OAS in IP VS IV therapy	<b>54</b>
<b>۲.۶</b>	Study patients in GOG trial	<b>70</b>
<b>۲.۷</b>	A) progression free survival B) overall survival	<b>74</b>
<b>۲.۸</b>	Placement of the catheter intraoperative	<b>84</b>
<b>۲.۹</b>	Intraoperative hyperthermic peritoneal perfusion	<b>86</b>
<b>۲.۱۰</b>	Toxicity associated in the GOG group 172 study	<b>93</b>

## LIST OF ABBREVIATIONS

<b>AUC</b>	<b>Area under the curve</b>
<b>IP</b>	<b>Intraperitoneal</b>
GFR	Glomerular filtration rate
HIIC	Hyperthermic intraoperative intraperitoneal chemotherapy
HRQOL	Health-related Quality of Life
GOG	Gynecology oncology group
FACT-O	Functional Assessment of Cancer Therapy-Ovarian
FIGO staging system	International Federation of Gynecology and Obstetrics staging system

# Introduction & Aim of work

## Introduction

Epithelial ovarian carcinoma is the leading cause of death from gynecologic malignancies in the developed world.

In 2005, it has been estimated that in the United States, 22,220 women will be diagnosed with ovarian cancer, and 16,210 women died from the disease (**Jemal et al., 2005**).

To date, no effective screening regimen for ovarian cancer has been identified. More than half of women with ovarian cancer present with advanced-stage disease (FIGO III/IV) at the time of diagnosis (**van Nagell et al., 1990**).

Epithelial ovarian cancer appears to arise from the epithelial surface of the ovary. Spread of the disease is often by local extension, by intra-abdominal dissemination to other sites within the peritoneal cavity, and by lymphatic spread to pelvic and para-aortic nodes in the retroperitoneum.

The recommended treatment includes primary surgery for diagnosis, staging, and cytoreduction, followed by chemotherapy (**Bolis et al., 1995**).

Unlike many other solid tumors, effective cytoreduction (“debulking”) conveys a survival benefit among women with ovarian carcinoma (**Michel et al., 1997**).

The goal of primary surgery is to reduce the burden of ovarian cancer to no or minimal residual disease.

The recommended initial chemotherapy is generally a platinum-and-taxane combination given by intravenous infusion every 3 weeks for 6-8 cycles (**Albert et al., 1996**).

For early ovarian cancer, appropriate surgical staging and adjuvant chemotherapy for selected cases will result in survival rates of 90–95%. For advanced ovarian cancer, survival

depends primarily on the success of the initial surgical procedure. Patients with complete cytoreduction to microscopic disease are often cured with adjuvant chemotherapy. **(Eisenkop and Spirato. 2001)**

As residual ovarian cancer after surgery and first recurrences are primarily confined to the abdomen, intraperitoneal (IP) administration of chemotherapy was first proposed several decades ago. Certain chemotherapeutic agents, including cisplatin and, more recently, paclitaxel, were found to have distinct pharmacokinetic advantages when given via an intraperitoneal route. These include high intraperitoneal concentration of drug, as well as a longer half-life of the drugs in the peritoneal cavity with lower systemic toxic effect compared to that observed with intravenous (IV) administration, for cisplatin there was a 10-20-fold greater exposure in the peritoneal cavity over what is achieved with the IV route **(Markman et al., 2001)**

There is growing evidence that patients with microscopic residual disease are excellent candidates for intraperitoneal chemotherapy, and this mode of chemotherapy delivery may be their best opportunity for cure. **(Albert et al., 1996)**

Patients with optimal cytoreduction also may benefit from intraperitoneal chemotherapy, but cure is less likely. For patients with suboptimal cytoreduction, intravenous chemotherapy with a combination of carboplatin and paclitaxel is the current standard therapy **(Yen et al., 2001)**

Intraperitoneal chemotherapy in combination with traditional surgery and chemotherapy, may result in further improvement in survival for patients with epithelial ovarian cancer

### ***The Aim of the study***

The aim of this study is to review the present status of IP chemotherapy in various stages of epithelial ovarian cancer and its cost effectiveness.

# Chapter 1

## Chapter 1

### CLINICAL PROFILE & TREATMENT OF EPITHELIAL OVARIAN CANCER